Expert Analysis

Genitourinary Cancers

Source: CCO Independent Conference Coverage of the 2008 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Genitourinary Cancers

Program Director: Ramaswamy Govindan, MD

Faculty:

David I. Quinn, MD, PhD
Brian I. Rini, MD
Nicholas J. Vogelzang, MD

Robert S. Mocharnuk, MD

CME CREDIT INFORMATION

Release Date: 08/19/08

Expiration Date: 08/18/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data from recent studies regarding current standards of care for patients with genitourinary cancer
Describe new data on novel agents and therapeutic approaches for patients with genitourinary cancer
Identify new agents and treatment strategies appropriate for the clinical management of patients with genitourinary cancer

Topics covered include:

Satraplatin in Patients With Advanced Hormone-Refractory Prostate Cancer: Overall Survival Results From the SPARC Trial
Antitumor Activity of Abiraterone Acetate in Previously Untreated and Docetaxel-Pretreated Castration-Resistant Prostate Cancer
Additional Comments on Prostate Cancer Therapy
First-line Treatment With Sunitinib vs Interferon alfa for Metastatic Renal Cell Carcinoma
Update on AVOREN Trial in Metastatic Renal Cell Carcinoma: Efficacy and Safety and Pharmacokinetic Analysis
Interferon Monotherapy vs Interferon Combination Therapy for mRCC
Everolimus vs Placebo in mRCC After Progression on VEGFr-TKI Therapy
Peripheral Blood Gene Expression Profiling in Bladder Cancer
Best Supportive Care Alone and With Vinflunine as Second-Line Therapy in Advanced Transitional Cell Carcinoma of the Urothelium
Gemcitabine/Paclitaxel as Second-Line Chemotherapy in Advanced Bladder Cancer: Temporary vs Maintenance Treatment
Radiotherapy vs Carboplatin for Stage I Seminoma: Updated Analysis of the MRC/EORTC Randomized Trial

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.